Dihexa (5mg & 10mg)

Dihexa (5mg & 10mg): A Synthetic Hexapeptide Analogue of Angiotensin IV Developed at Washington State University as a Potent Nootropic and Neuroprotective Agent That Acts Through Allosteric Modulation of the Hepatocyte Growth Factor (HGF)/c-Met Receptor Pathway — Promoting Synaptogenesis, Neuronal Survival, and Cognitive Enhancement, with Preclinical Evidence of Rescue of Cognitive Impairment in Alzheimer's Disease Mouse Models via PI3K/AKT Signaling and Anti-Inflammatory Mechanisms

Dihexa (development code PNB-0408; chemical name N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small synthetic oligopeptide that has emerged as one of the most intriguing candidates in the field of cognitive enhancement and neurodegenerative disease research. Developed over a two-decade research arc by Dr. Joseph Harding and colleagues at Washington State University, Dihexa represents a deliberate structural and functional evolution from its parent molecule, angiotensin IV (AngIV) — a hexapeptide fragment of the renin-angiotensin system that was first identified in the 1980s as having unexpected effects on memory and cognition when administered centrally. The path from angiotensin IV to Dihexa involved a systematic program of medicinal chemistry optimization aimed at addressing the two primary limitations of native AngIV: its rapid metabolic degradation (half-life measured in minutes) and its inability to cross the blood-brain barrier when administered systemically. By chemically modifying the parent angiotensin IV structure with an N-hexanoyl cap on a tyrosine-isoleucine dipeptide core, linked through a 6-aminohexanoic acid spacer, the WSU research team created a compound that retains and amplifies the cognitive-enhancing properties of the original while offering superior blood-brain barrier penetration, metabolic stability, and oral bioavailability — properties that are essential for a systemically administered cognitive enhancer. The resulting molecule, Dihexa, has been characterized in preclinical studies as an extraordinarily potent promoter of synaptogenesis (the formation of new synaptic connections between neurons), with some early reports claiming potency up to seven orders of magnitude greater than brain-derived neurotrophic factor (BDNF) at promoting new synapse formation in hippocampal neuron cultures — although this specific claim has been the subject of scientific debate and retraction concerns, as discussed in more detail below. Regardless of the exact potency relative to BDNF, the weight of preclinical evidence supports Dihexa as a genuinely novel cognitive enhancer with a mechanism of action that is distinct from all other currently available nootropic agents^{[1][2][3][4][5][6][7][8][9][10]}.

Mechanism of Action: The HGF/c-Met Pathway and Synaptogenesis

The mechanism of action of Dihexa centers on the hepatocyte growth factor (HGF)/c-Met receptor signaling axis — a pathway with well-established roles in embryonic development, tissue regeneration, wound healing, and, critically, brain development, neuroplasticity, and neuroprotection. Unlike direct receptor agonists that bind to and activate the c-Met receptor themselves, Dihexa acts as an allosteric modulator and potentiator of HGF signaling — it binds to and stabilizes hepatocyte growth factor, preventing its enzymatic degradation and facilitating its dimerization and binding to the c-Met receptor tyrosine kinase. This is a subtle but important mechanistic distinction: Dihexa does not substitute for endogenous HGF or directly activate c-Met in the absence of HGF; rather, it amplifies and prolongs the signaling of endogenous HGF by increasing its effective concentration and biological activity at the receptor. This allosteric potentiation mechanism is analogous to how a positive allosteric modulator of a GABA-A receptor (such as a benzodiazepine) amplifies the effect of endogenous GABA without directly activating the receptor itself — a mechanism that can offer advantages in terms of physiological regulation and reduced risk of overstimulation. Once HGF binding to c-Met is enhanced by Dihexa, the activated c-Met receptor tyrosine kinase triggers a cascade of downstream signaling pathways, most notably the PI3K/AKT pathway, which is central to neuronal survival, synaptic plasticity, and memory consolidation. Activated AKT phosphorylates a range of downstream targets that promote cell survival (inhibition of pro-apoptotic factors like BAD and caspase-9), protein synthesis (activation of mTOR and p70S6K), and synaptic remodeling (regulation of actin cytoskeleton dynamics and AMPA receptor trafficking). In addition to the PI3K/AKT pathway, HGF/c-Met activation also engages the MAPK/ERK pathway, which is involved in cell proliferation, differentiation, and neurite outgrowth, and the STAT3 pathway, which plays roles in neuroinflammation and gene expression regulation. The net effect of these signaling cascades in the brain is the promotion of synaptogenesis — the physical formation of new synaptic connections between neurons — particularly in the hippocampus, a brain region critical for learning and memory that is also one of the few areas of the adult brain where neurogenesis (the birth of new neurons) continues throughout life. In preclinical studies, Dihexa has been shown to increase the density of dendritic spines (the small protrusions on dendrites that receive synaptic input) and to increase the expression of synaptic proteins such as synaptophysin (SYP), a marker of synaptic density and presynaptic function. An additional and increasingly recognized aspect of Dihexa's mechanism is its interaction with the angiotensin IV receptor (AT4 receptor), which has been identified as insulin-regulated aminopeptidase (IRAP) — an enzyme that is highly expressed in the brain and is involved in the regulation of cognitive function through its role in the metabolism of neuropeptides including oxytocin, vasopressin, and somatostatin. Dihexa, as an angiotensin IV analogue, binds to and inhibits IRAP, potentially increasing the levels of these cognition-enhancing neuropeptides in the brain. The relative contribution of the HGF/c-Met pathway versus the IRAP/AT4 receptor pathway to Dihexa's overall cognitive effects remains an area of active research, and it is likely that both mechanisms contribute to its nootropic profile, with the HGF/c-Met pathway being primarily responsible for the synaptogenic and neurotrophic effects and the IRAP inhibition contributing to acute cognitive enhancement through neuropeptide modulation^{[1][2][3][4][5][6][7][8][9][10]}.

Preclinical Evidence: Cognitive Enhancement, Neuroprotection, and Alzheimer's Disease Models

The preclinical evidence for Dihexa spans more than a decade of research, encompassing in vitro studies in cultured neurons, in vivo studies in animal models of cognitive impairment and neurodegeneration, and investigations into its mechanism of action and safety profile. The foundational work, published in 2013 by the WSU research group, described Dihexa as a metabolically stable angiotensin IV analogue that improved cognitive performance in scopolamine-impaired rats (a standard model of acute cognitive deficit) and promoted synaptogenesis in cultured hippocampal neurons. In the scopolamine model, rats treated with Dihexa showed significant improvements in spatial learning and memory in the Morris water maze test — a widely used behavioral assay that measures the ability of rodents to learn and remember the location of a hidden platform in a pool of water, relying on spatial cues in the environment. The cognitive improvements observed with Dihexa were comparable to or greater than those seen with established cognitive enhancers such as donepezil (an acetylcholinesterase inhibitor used in Alzheimer's disease) and were achieved at very low doses, consistent with the compound's high potency. The in vitro synaptogenesis studies showed that Dihexa increased the number of synaptic connections in cultured hippocampal neurons, as measured by immunofluorescence staining for synaptic markers and by electrophysiological recordings of synaptic activity. A follow-up study published in 2014 claimed that Dihexa was "seven orders of magnitude more potent than BDNF" at promoting new synaptic connections — a claim that generated considerable attention in the research community but has subsequently been the subject of scientific debate. The original paper (Benoist et al., 2014) was retracted by the journal due to concerns about data integrity and reproducibility, and while the synaptogenic activity of Dihexa has been confirmed by independent groups, the specific claim of seven-orders-of-magnitude greater potency than BDNF should be viewed with caution and is not considered a well-established finding. More recent and methodologically rigorous studies have focused on Dihexa's potential therapeutic effects in Alzheimer's disease models. A 2021 study published in the Journal of Alzheimer's Disease (PMC8615599) investigated the effects of Dihexa in the APP/PS1 mouse model of Alzheimer's disease — a transgenic model that expresses mutant human amyloid precursor protein (APP) and presenilin-1 (PS1), leading to the accumulation of amyloid-beta plaques and progressive cognitive impairment reminiscent of Alzheimer's disease. In this study, Dihexa treatment restored spatial learning and cognitive functions in the Morris water maze test, increased the number of healthy neurons and the expression of synaptophysin (SYP) protein (as measured by Nissl staining and immunohistochemistry), decreased the activation of astrocytes and microglia (the two primary glial cell types involved in neuroinflammation), markedly reduced levels of pro-inflammatory cytokines including IL-1β and TNF-α, and increased levels of the anti-inflammatory cytokine IL-10. These findings suggest that Dihexa exerts its therapeutic effects in this Alzheimer's model through a combination of mechanisms: direct neurotrophic and synaptogenic effects (via HGF/c-Met/PI3K/AKT signaling), anti-inflammatory effects (reducing glial activation and pro-inflammatory cytokine production), and potentially amyloid-beta clearance or reduction (although this latter mechanism requires further investigation). The PI3K/AKT signaling pathway was specifically implicated as the primary mediator of Dihexa's effects in this study, consistent with the proposed mechanism of HGF/c-Met allosteric potentiation. Additional preclinical studies have investigated Dihexa's effects in other models of neurological dysfunction, including models of traumatic brain injury, stroke, and depression, with generally encouraging results showing neuroprotective and cognitive-enhancing effects across multiple paradigms. It is important to note that, as of 2026, Dihexa has not progressed to human clinical trials — all available evidence is preclinical (in vitro and animal studies), and the safety, efficacy, and pharmacokinetics of Dihexa in humans remain uncharacterized. The research-grade Dihexa supplied by Amideworks is intended for laboratory and investigational use only, not for human consumption or therapeutic use, and any use outside of approved research protocols is off-label and potentially dangerous^{[1][2][3][4][5][6][7][8][9][10]}.

Key Research Considerations and Scientific Caveats: Dihexa represents a genuinely novel approach to cognitive enhancement and neurodegenerative disease therapy, with a mechanism of action (allosteric potentiation of HGF/c-Met signaling + IRAP inhibition) that is distinct from all other currently available nootropic agents, including acetylcholinesterase inhibitors (donepezil, rivastigmine), NMDA receptor antagonists (memantine), AMPAkines, and racetams (piracetam, aniracetam). Several important considerations and caveats merit emphasis for researchers and anyone evaluating the Dihexa literature: (1) The "seven orders of magnitude more potent than BDNF" claim is not well-established — the original 2014 paper making this claim (Benoist et al.) was retracted by the journal due to data integrity concerns, and while Dihexa's synaptogenic activity has been independently confirmed, the specific potency comparison to BDNF should be viewed as preliminary and not as a settled finding; researchers should avoid citing this specific claim as established fact. (2) All available evidence is preclinical as of 2026 — Dihexa has not progressed to human clinical trials, and its safety, efficacy, pharmacokinetics, and pharmacodynamics in humans remain completely uncharacterized; extrapolation from animal studies to humans should be done with appropriate caution, as many compounds that show promising effects in rodent models fail to translate to clinical efficacy or acceptable safety in humans. (3) The HGF/c-Met pathway has complex and sometimes contradictory roles in cancer biology — c-Met is a proto-oncogene that is dysregulated in many human cancers, and while HGF/c-Met activation is generally considered neurotrophic and neuroprotective in the central nervous system, the theoretical possibility of systemic c-Met activation promoting tumor growth or progression is a safety consideration that warrants careful evaluation, particularly in individuals with a history of cancer or elevated cancer risk; this concern is somewhat mitigated by Dihexa's allosteric potentiation mechanism (which amplifies endogenous HGF rather than directly activating c-Met) but cannot be entirely dismissed. (4) The relative contribution of the two proposed mechanisms (HGF/c-Met vs IRAP/AT4) remains incompletely understood — while both pathways have been implicated in Dihexa's effects, the precise balance between synaptogenic/neurotrophic effects (primarily HGF/c-Met mediated) and acute cognitive-enhancing effects (potentially IRAP-mediated through neuropeptide modulation) requires further investigation; this mechanistic uncertainty is common in early-stage drug development and does not diminish the compound's research interest. (5) Blood-brain barrier penetration and systemic stability are key advantages — unlike native angiotensin IV and many other peptide-based cognitive enhancers that require intracerebroventricular administration due to poor BBB penetration, Dihexa was specifically engineered for systemic availability and has demonstrated central activity after peripheral administration in animal studies, making it a more practical research tool and potential therapeutic candidate. (6) Research applications for Dihexa include investigations of HGF/c-Met signaling in synaptic plasticity and memory, studies of IRAP/AT4 receptor biology and neuropeptide regulation, preclinical evaluations in Alzheimer's disease and other neurodegenerative models, investigations of synaptogenesis and dendritic spine dynamics, studies of neuroinflammation and glial activation, and explorations of cognitive enhancement in normal aging and age-related cognitive decline^{[1][2][3][4][5][6][7][8][9][10]}.

References

1. Dihexa.co.uk. What Is Dihexa? Complete Guide to PNB-0408. dihexa.co.uk. 2026. (Structural analogue of angiotensin IV designed as more potent and selective activator of HGF/c-Met pathway in brain while minimizing cardiovascular effects; chemically modified with hexanoic acid chains; retains cognitive-enhancing properties with superior BBB penetration and metabolic stability; deliberate shift away from cardiovascular angiotensin effects)
2. Protosi Health. Dihexa: The HGF/MET-Potentiating Nootropic Peptide Research Guide. protosi.health. 2026. (Developed at Washington State University by Joseph Harding and colleagues; binds to hepatocyte growth factor (HGF) and potentiates its action at MET receptor; pathway with significant roles in neuronal survival, synaptogenesis, and memory consolidation; proposed mechanism centres on HGF/MET signalling axis)
3. PeptideWise. Dihexa. getpeptidewise.com. 2026. (Angiotensin system interaction: as Angiotensin IV analog, interacts with angiotensin IV receptors (AT4/IRAP), though exact contribution vs c-Met activation is ongoing research; Blood-brain barrier penetration: key feature over native HGF (large protein) is ability to cross BBB — essential for CNS effects when given systemically; engineered into molecule during development)
4. PMC / Journal of Alzheimer's Disease. AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. J Alzheimers Dis. 2021;84(1):257-272. PMC8615599. (Dihexa restored spatial learning and cognitive functions in Morris water maze; increased neuronal cells and SYP protein expression in APP/PS1 mice (Nissl staining); decreased activation of astrocytes and microglia; reduced pro-inflammatory cytokines IL-1β and TNF-α; increased anti-inflammatory cytokine IL-10; N-hexanoic-Tyr-Ile-(6) aminohexanoic amide; PI3K/AKT pathway implicated)
5. RethinkPeptides. Dihexa's Potency Claims: What the Research Says. rethinkpeptides.com. 2026. (Formally known as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide; described in 2013 paper as metabolically stable angiotensin IV analog that improved cognitive performance in scopolamine-impaired rats and promoted synaptogenesis in hippocampal neurons; follow-up 2014 study claimed "seven orders of magnitude more potent than BDNF" at promoting new synaptic connections; central mechanism paper [Benoist 2014] has been retracted — important caveat)
6. Peptide-Reference. Dihexa. peptide-reference.com. 2026. (Mechanism centers on HGF/c-Met receptor system, critical for brain development, neuroplasticity, neuroprotection; acts as allosteric modulator and potentiator of HGF signaling — facilitates HGF dimerization and binding to c-Met receptor tyrosine kinase, amplifying downstream signaling cascade; activated c-Met triggers PI3K/Akt pathway [neuronal survival, synaptogenesis, memory consolidation])
7. PepTutor. Dihexa. peptutor.net. 2026. (Binds to and stabilizes hepatocyte growth factor (HGF), preventing enzymatic degradation; stabilized HGF signals more intensely through c-Met receptor; distinct from direct c-Met agonism — amplifies endogenous HGF activity rather than substituting; enhanced c-Met activation triggers PI3K/AKT signaling pathway, drives synaptogenesis: physical formation of new synaptic connections; HGF expressed throughout brain)
8. Kalios Health. Dihexa Preclinical. kalios.health. 2026. (Proposed mechanism based on WSU papers with caveat that central mechanism paper [Benoist 2014] has been retracted; HGF/c-Met receptor positive modulation; path from angiotensin IV to dihexa to HGF/c-Met evolved through two-decade research arc; Angiotensin IV parent — endogenous AngIV (hexapeptide fragment of angiotensin II) has known effects on memory and cognition; breaks down quickly and cannot cross BBB; Dihexa engineered for stability)
9. High Peptides. Dihexa: The Most Potent Nootropic Peptide? highpeptides.com. 2026. (Dihexa [PNB-0408] is hexapeptide derived from angiotensin IV; works by activating HGF/c-Met receptor pathway, promotes synaptogenesis — formation of new synaptic connections between neurons; developed at Washington State University by Dr. Joseph Harding's lab; question of "10 million times more potent than BDNF" addressed with caveats)
10. PeptideJournal. Dihexa: Cognitive Peptide Research Profile. peptidejournal.org. 2025. (Small synthetic peptide — technically an oligopeptide — designed to mimic and amplify activity of angiotensin IV, fragment of renin-angiotensin system with known effects on memory and cognition; unlike angiotensin IV which breaks down quickly and cannot cross BBB, Dihexa engineered for stability; structure includes N-hexanoyl cap on tyrosine-isoleucine dipeptide core, with 6-aminohexanoic acid spacer)